Succinylcholine (suxamethonium)
سوکسینیلکولین (ساکسامتونیوم)
🦴 Musculo-Skeletal SystemDepolarising neuromuscular blocker
Market / country: 🇺🇸 USA
Quelicin / Anectine (US)
🧮 Dose calculator
Tracheal intubation and neuromuscular blockade · Regimen source: FDA Quelicin · 2.2
- • Only with full airway and ventilation support available. FDA Quelicin · 2.1
Enter age and weight.
🛡️ Safety & information
Contraindications
- ⛔ Skeletal muscle myopathies; after the acute phase of major burns, multiple trauma, extensive denervation or upper motor neuron injury (hyperkalaemia and cardiac arrest); personal or family history of malignant hyperthermia; hypersensitivity. FDA Quelicin · 4
Warnings
- • Boxed warning: rhabdomyolysis with hyperkalaemia, ventricular dysrhythmias, cardiac arrest and death in apparently healthy children with undiagnosed myopathy (mostly Duchenne). Malignant hyperthermia. FDA Quelicin · Boxed WarningFDA Quelicin · 5
Formulations
- 20 mg/mL (200 mg/10 mL multiple-dose vial) — injection 🇺🇸 USA FDA Quelicin · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Quelicin · 8.1
“Risk Summary Available data from published literature from case reports and case series over decades of use with succinylcholine during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Quelicin · 8.2
“Risk Summary There are no data on the presence of succinylcholine or its metabolite in either human or animal milk, the effects on the breastfed infant, or the effects on milk production.”
- 👶 ChildrenDangerous / avoid
Boxed warning in the label about children. FDA Quelicin · Boxed Warning
“• Acute rhabdomyolysis with hyperkalemia followed by ventricular dysrhythmias, cardiac arrest, and death has occurred after the administration of succinylcholine to apparently healthy pediatric patients who were subsequently found to have undiagnosed skeletal muscle myopathy, most frequently Duchenne muscular …”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Quelicin · 8.5
“In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA008845
- DailyMed (FDA label)FDA Quelicin
- MedlinePlus (NIH)❌ None
- WHO ATC/DDDM03AB01
- Darooyab (Iran)❌ None
🇮🇷 Not found in Iran list Darooyab · search
Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Quelicin · 3FDA Quelicin · 2.2FDA Quelicin · 2.1FDA Quelicin · 2.3FDA Quelicin · 2.4FDA Quelicin · 4FDA Quelicin · Boxed WarningFDA Quelicin · 5FDA Quelicin · SPL approval / marketing categoryFDA Quelicin · 8.1FDA Quelicin · 8.2FDA Quelicin · 8.5
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · search
- Clinical review⚠ Unverified